PB1768: IS NATIVE E-COLI OR PEG-ASPERAGINASE FORMULATION A HIGHER RISK FOR VTE DEVELOPMENT IN PATIENTS WITH POST TREATMENT ACUTE LYMPHOBLASTIC LEUKEMIA? A META-ANALYSIS by J. T. Seki, E. Atenafu, H. Sibai

Get full text

ICSI cycles in women over 40 years: analysis of 3 different ovarian stimulation protocols by H. Sibai, E.A. Elgindy, M.I. Mostafa

Get full text

P502: CLINICAL IMPLEMENTATION OF GERMLINE GENETIC TESTING FOR HEMATOLOGIC DISORDERS by S. Ansar, J. Malcolmson, K. M. Farncombe, K. Yee, R. H. Kim, H. Sibai

Get full text

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS by M. Davidson, F. Wong, M. Atri, H. Sibai, D. Maze, V. Cheung, T. Nye, J. Callum, E. Atenafu, V. Gupta

Get full text

P352: SYMPTOMATIC VTE INCIDENCE IN ADULT ALL TREATED WITH PEG-ASPARAGINASE COMPARED TO THE NATIVE L-ASPARAGINASE IN WITH AN ASPARAGINASE-BASED PROTOCOL by R. Chen, J. Seki, L. Liu, E. Atenafu, K. Yee, A. Schuh, V. Gupta, S. Chan, A. Schimmer, D. Maze, M. Minden, H. Sibai

Get full text

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY by F. Passamonti, J. Foran, A. Tandra, V. De Stefano, M. Laura Fox, A. Mattour, M. F. McMullin, A. C. Perkins, G. Rodriguez-Macías, H. Sibai, Q. Qin, J. Potluri, J. How

Get full text

P500: A REAL WORLD MULTI CENTRE STUDY OF CPX-351 REVEALS NO DIFFERENCE IN OVERALL SURVIVAL WHEN COMPARED WITH FLAG-IDA AND 3 + 7 IN HIGH RISK AML. by C. Andrews, I. AlNabhani, T. Young, E. G. Atenafu, S. E. Assouline, J. M. Brandwein, S. M. Chan, S. Chow, D. Khalaf, V. Gupta, D. D. H. Kim, D. Maze, M. M. Minden, T. Murphy, D. Sanford, A. D. Schimmer, A. C. Schuh, J. Sibai, K. Yee, H. Sibai

Get full text